This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Cambridge Mobile decision designated informative as AIA tweaks continue

By Melissa Ritti ( March 20, 2025, 19:05 GMT | Insight) -- The US Patent and Trademark Office announced today that a December 2024 decision by the Patent Trial and Appeal Board in an inter partes review initiated by Cambridge Mobile Telematics has been designated informative. While carrying less weight than a designation of precedential, the move signals an intent by the PTAB to hold petitioners accountable for advancing inconsistent positions in parallel district court litigation. It comes just weeks after the USPTO rescinded the guidelines articulated by a prior director regarding discretionary denial of America Invents Act post-grant review proceedings.A Dec. 13, 2024 decision by the US Patent and Trademark Office’s Patent Trial and Appeal Board that discretionarily denied a petition for inter partes review, or IPR, by Cambridge Mobile Telematics has been designated informative....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections